It's All One Trial: a continuous master-protocol framework to accelerate development and confirmation of disease-modifying therapies for type 1 diabetes

This publication has 18 references indexed in Scilit:

• Improving phase 2/3 trials with an enhanced 2-in-1 adaptive design
  Contemporary Clinical Trials Communications, 2025
• Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
  New England Journal of Medicine, 2025
• A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
  New England Journal of Medicine, 2024
• Teplizumab and β-Cell Function in Newly Diagnosed Type 1 Diabetes
  New England Journal of Medicine, 2023
• C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis
  The Lancet Diabetes & Endocrinology, 2023
• Quantifying beta cell function in the preclinical stages of type 1 diabetes
  Diabetologia, 2023
• The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
  Diabetologia, 2021
• Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both
  New England Journal of Medicine, 2017
• Optimal design of multi‐arm multi‐stage trials
  Statistics in Medicine, 2012
• Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
  Trials, 2009